(Q35198543)

7 August 2017

1 reference

title

Selective estrogen-receptor modulators. (English)

1 reference

7 August 2017

Felicia Cosman

1

1 reference

7 August 2017

publication date

1 May 2003

1 reference

Clinics in geriatric medicine

7 August 2017

published in

1 reference

7 August 2017

volume

19

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

371-379

1 reference

Selective estrogen receptor modulators: clinical spectrum

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effect of long term tamoxifen treatment on bone turnover in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Coronary heart disease mortality and adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Tamoxifen and the uterus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Symptoms associated with tamoxifen treatment in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Raloxifene effect on frequency of surgery for pelvic floor relaxation

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Cognitive function in postmenopausal women treated with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

Mood effect of raloxifene in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0690%2802%2900114-3

7 January 2021

10.1016/S0749-0690(02)00114-3

Identifiers

DOI

1 reference

7 August 2017

1 reference